USA flag logo/image

An Official Website of the United States Government

PhotoMorph3 and PhotoPS3 - Novel Light-Activated Antisense Agents

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93867
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
GM088964
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
SYNTRIX BIOSYSTEMS, INC.
215 CLAY ST NW, STE B-5 AUBURN, WA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: PhotoMorph3 and PhotoPS3 - Novel Light-Activated Antisense Agents
Agency: HHS
Contract: 1R43GM088964-01
Award Amount: $698,900.00
 

Abstract:

DESCRIPTION (provided by applicant): The spatiotemporal modulation of gene expression using targeted light to activate antisense molecules promises to have an important impact in transparent model organisms, where irradiation can be specifically targeted visually to known anatomic landmarks. Irradiating selected cells within organs permits specific genes to be turned off at any time during the development of the organism with cell-scale resolution, thereby permitting an in depth spatiotemporal understandin g of the role of particular genes in the whole organism. This also allows the study of genes essential in early development that otherwise result in a lethal phenotype. We have developed a commercial reagent, software and instrumentation platform for condu cting spatiotemporal gene-control experiments. Leveraging off these initial successes, we now aim to further develop and commercialize a new generation of photoactivatable antisense reagents (PhotoMorph3.0 and PhotoPS3.0 ). The proposed photoactivatable a ntisense reagents are based on morpholino or phosphorthioate oligomers that are protected on their exocyclic hydrogen bond donors and acceptors with photolabile caging groups that disrupt Watson-Crick pairing with a target mRNA. Light irradiation cleaves t he caging groups, freeing the bases to participate in hybridization with the target. We hypothesize that exocyclic base protection will offer important advantages over other photoactivatable formats, including a 'tight' off-state and facile on-demand acces s using automation. The goal of this Phase I SBIR is to make the photoactivatable antisense chemistry robust for commercial-scale synthesis and implementation. The goal of the Phase II SBIR will be to develop validated and turn-key tool-kits for various developmental pathways (e.g. gut400, CNS500), where the basic phenotype of each photoactivatable antisense reagent will be described and made available in a public database for researchers. PUBLIC HEALTH RELEVANCE: The modulation of gene expression at different times and locations using targeted light to activate molecules promises to have an important impact in transparent model organisms, where irradiation can be specifically targeted visually to known anatomic landmarks. Irradiating selected cell s within organs permits specific genes to be turned off at any time during the development of the organism with cell-scale resolution, thereby permitting an in depth understanding of the role of particular genes in different locations in the whole organism and at different times during its development. We now aim to further develop and commercialize a new generation of photoactivatable chemicals for doing this (PhotoMorph3.0 and PhotoPS3.0 ) that we believe will offer important advantages over others.

Principal Investigator:

Joel R. Morgan
2538338009
JMORGAN@SYNTRIXBIO.COM

Business Contact:

Dee Hoeke
dhoeke@syntrixbio.com
Small Business Information at Submission:

SYNTRIX BIOSYSTEMS, INC.
SYNTRIX BIOSYSTEMS, INC. 215 CLAY ST NW, STE B-5 AUBURN, WA 98001

EIN/Tax ID: 911981291
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No